entertainment -WSS

entertainment

author：hotspot 2025-09-27 15:59:07 - browse：7

Mathai Mammen crosses his arms and looks into the camera — coverage from STAT — FogPharma CEO Mathai Mammen Boston Globe Photo Import

Oncology startup FogPharma just closed a $145 million Series E round, the company confirmed, reaching a late stage of financing that few other biotechs have hit in recent years.

FogPharma, which is headquartered in Cambridge, Mass., is developing cancer treatments using corkscrew-shaped peptides called helicons that could possibly better breach cells.

As CEO Mathai Mammen sees it, very few exemplary medicines shuttle off of drug companies’ pipelines, wade through clinical trials, and end up in the hands of physicians and patients in a given year. Far more often, pharma and biotech companies are pushing out drugs that are incrementally better than what came before, extending cancer patients’ survival by a few more months, halting their tumor growth for a little while longer. But FogPharma could deliver something truly unique, Mammen said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Cybersecurity threat forces Lurie Children's to take systems offline

WSS

With trial win, GSK could get blood cancer drug back on market

Cybersecurity threat forces Lurie Children's to take systems offline

Cord blood banking comes at a high cost to babies

Let's speed up science by embracing open access publishing

Let's speed up science by embracing open access publishing

NIH documents show early flaws of $1.6 billion long Covid program

focus

entertainment

Wikipedia

Hollywood unions extend contract negotiations for actors

Commercial surrogacy can be ethical, despite pope’s claims

Wildfire smoke exposes gaps in outdoor worker protections

How to increase colonoscopy rates? Looks like an AI can help

Bright Health sells Medicare Advantage business to Molina

Some dementia cases could be undiagnosed liver disease

Medical records are filled with copy

Ionis drug prevents swelling attacks due to hereditary angioedema

After affirmative action ruling, medical educators look to 'holistic review'

Vertigo drug brings hope for rare neuron disorder, Niemann

hotspot

Innovation in antibiotics is ailing. 'Brain drain' may kill it

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Shifting the focus from loneliness to social health

Cybersecurity threat forces Lurie Children's to take systems offline

Covid misinformation case heads to Supreme Court

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

knowledge

focus

focus

focus